Skip to content
Science
Our Science
Autoimmunity
P140
Type M & Diagnostic
Type 1 Diabetes
Kapiglucagon
Anti-infectives
BioAMB
BioCIN
Pipeline
Company
Mission
About Us
Our Team
ImmuPharma Biotech
Investors
Investors
AIM Rule 26 Information
Regulatory News
Corporate Governance
Board of Directors
Annual Reports
Advisers
Email Alert
Updates
Announcements
Interviews
In the Media
Contact
Analyst Research by Dr Martin Hall
Mar 7, 2023
ImmuPharma research notes can be accessed either via:
Stanford Capital Partners
click here
Research Tree
click here
←
Previous:
Phase 2/3 adaptive study design for Lupus study agreed with Avion
Next:
Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy
→
